Aricept, an acetylcholinesterase inhibitor developed by Eisai, is claimed to be the only approved prescription medicine for the treatment of Alzheimer’s disease in Japan. It is believed to
Under the terms of the agreement, Transition will receive a $7 million upfront payment, and may also receive up to $130 million in potential development and sales milestones,
According to the report released by IMS, the total US prescription sales reached $286.5 billion, with slower sales growth resulting from loss of exclusivity of branded medicines, fewer
The drug which was initially discovered at Imperial College was based on a gut hormone called oxyntomodulin that helped obese people lose weight by lowering their appetite and
This double-blind, placebo-controlled clinical trial is designed to assess the efficacy and safety of Vilazodone. It will also further evaluate genetic biomarkers of response to Vilazodone, which may
The results were taken from two sub-analyses of fistula patients from Abbott’s 854-patient, one-year Phase III Charm trial for Humira. Patients were followed through a second year of
The Phase I study is an open-label, dose-escalation clinical trial in patients with non-resectable or metastatic solid tumors. The primary objectives of the clinical protocol submitted with the
In addition, Catholic Healthcare West (CHW) has received Institutional Review Board approval for the clinical trial, which is expected to begin soon. Advanced Cell Technology’s (ACT) myoblast program
Under the terms of the agreement, AVI will issue up to $7.5 million in AVI common stock valued at $1.3161 per share in exchange for all outstanding shares
Under the terms of the agreement, M’s Science will grant Eisai the following rights in exchange for a certain payment: the first review right for evaluating the results
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.